MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

AVE 0991

CAS No. : 304462-19-9

MCE 站：AVE 0991

产品活性：AVE 0991 是一种有效的非肽Ang-(1-7) 受体 Mas 激动剂。AVE 0991 与 [¹²⁵I]-Ang-(1-7) 竞争性地结合到牛主动脉内皮细胞膜，IC₅₀ 为 21 nM。

研究领域：GPCR/G Protein

作用靶点：Angiotensin Receptor

In Vitro: AVE 0991 is a nonpeptide compound that evokes effects similar to Ang-(1-7) on the endothelium. AVE 0991 and unlabeled Ang-(1-7) compete for high-affinity binding of [¹²⁵I]-Ang-(1-7) to bovine aortic endothelial cell membranes with IC₅₀s of 21±35 and 220±280 nM, respectively. Peak concentrations of NO and O₂^- release by AVE 0991 sodium salt and Ang-(1-7) (both 10 μM) are not significantly different (NO: 295±20 and 270±25 nM; O₂^-: 18±2 and 20±4 nM). However, the released amount of bioactive NO is ≈5 times higher for AVE 0991 in comparison to Ang-(1-7).

In Vivo: AVE 0991 (0.58 nmol/g) produces a significant decrease of water diuresis in WT mice compared with vehicle-treated animals (0.06±0.03 mL versus 0.27±0.05; n=9 for each group; P<0.01). The antidiuretic effect of AVE 0991 (AVE) is associated with an increase in urine osmolality (1669±231.0 mOsm/KgH₂O versus 681.1±165.8 mOsm/KgH₂O in vehicle-treated mice; P<0.01). The genetic deletion of Mas abolishes the antidiuretic effect of AVE 0991 during water loading (0.37±0.10 mL [n=9] versus 0.27±0.03 mL [n=11] in AVE 0991-treated mice). As observed with C57BL/6 mice, administration of AVE 0991 (0.58 nmol/g) in water-loaded Swiss mice also produces a significant decrease of the urinary volume compared with vehicle-treated animals (0.13±0.05 mL [n=16] versus 0.51±0.04 mL [n=40]; P<0.01). One week of treatment with AVE-0991 produces a significant decrease in perfusion pressure (56.55±0.86 vs. 68.73±0.69 mmHg in vehicle-treated rats) and an increase in systolic tension (11.40±0.05 vs. 9.84±0.15 g in vehicle-treated rats), rate of tension rise (+dT/dt; 184.30±0.50 vs. 155.20±1.97 g/s in vehicle-treated rats), rate of tension fall (?dT/dt; 179.60±1.39 vs. 150.80±2.42 g/s in vehicle-treated rats). A slight increase in heart rate (HR) is also observed (220.40±0.71 vs. 214.20±0.74 beats/min in vehicle-treated rats.

相关产品：Covalent Screening Library Plus  |  Bioactive Compound Library Plus  |  GPCR/G Protein Compound Library  |  Covalent Screening Library  |  Anti-Cardiovascular Disease Compound Library  |  Endocrinology Compound Library  |  Orally Active Compound Library  |  Neurotransmitter Receptor Compound Library  |  Angiotensin II human  |  Losartan  |  A 779  |  Telmisartan  |  PD 123319 ditrifluoroacetate  |  Valsartan  |  Olmesartan  |  Tranilast  |  YS-49  |  Irbesartan  |  Candesartan  |  CGP-42112  |  Olodanrigan  |  Sparsentan  |  C-Type Natriuretic Peptide (CNP) (1-22), human  |  Azilsartan medoxomil  |  AVE 0991 sodium salt  |  Angiotensin II 5-valine  |  Eprosartan mesylate  |  Angiotensin (1-7) (acetate)  |  Fimasartan  |  Tasosartan  |  Angiotensin II (3-8), human TFA  |  Brain Natriuretic Peptide (1-32), rat acetate

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。